The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Achillion Pharmaceuticals, Inc. | COM | 00448Q201 | 5,906 | 1,779,340 | SH | DFND | 3 | 0 | 0 | 0 | |
| Alexion Pharmaceuticals, Inc. | COM | 015351109 | 100,650 | 757,428 | SH | DFND | 2 | 0 | 0 | 0 | |
| Alnylam Pharmaceuticals, Inc. | COM | 02043Q107 | 30,304 | 471,288 | SH | DFND | 3 | 0 | 0 | 0 | |
| Ariad Pharmaceuticals, Inc. | COM | 04033A100 | 9,461 | 1,387,171 | SH | DFND | 3 | 0 | 0 | 0 | |
| Celgene Corp. | COM | 151020104 | 342,882 | 2,029,271 | SH | DFND | 2 | 0 | 0 | 0 | |
| Clovis Oncology Inc. | COM | 189464100 | 29,423 | 488,188 | SH | DFND | 3 | 0 | 0 | 0 | |
| Cubist Pharmaceuticals, Inc. | RIGHT 99/99/9999 | 229678123 | 1,183 | 876,273 | SH | DFND | 3 | 0 | 0 | 0 | |
| Endocyte, Inc. | COM | 29269A102 | 28,233 | 2,643,522 | SH | DFND | 3 | 0 | 0 | 0 | |
| Gilead Sciences, Inc | COM | 375558103 | 266,433 | 3,547,714 | SH | DFND | 1 | 0 | 0 | 0 | |
| Halozyme Therapeutics, Inc. | COM | 40637H109 | 70,827 | 4,724,936 | SH | DFND | 3 | 0 | 0 | 0 | |
| Idenix Pharmaceuticals, Inc. | COM | 45166R204 | 7,475 | 1,250,000 | SH | DFND | 3 | 0 | 0 | 0 | |
| ImmunoGen, Inc. | COM | 45253H101 | 47,323 | 3,225,816 | SH | DFND | 3 | 0 | 0 | 0 | |
| Incyte Corp. | COM | 45337C102 | 213,714 | 4,221,087 | SH | DFND | 3 | 0 | 0 | 0 | |
| Infinity Pharmaceuticals Inc. | COM | 45665G303 | 17,963 | 1,300,737 | SH | DFND | 3 | 0 | 0 | 0 | |
| Isis Pharmaceuticals, Inc. | COM | 464330109 | 255,675 | 6,417,548 | SH | DFND | 3 | 0 | 0 | 0 | |
| Medivation, Inc. | COM | 58501N101 | 94,435 | 1,479,706 | SH | DFND | 3 | 0 | 0 | 0 | |
| Neurocrine Biosciences, Inc. | COM | 64125C109 | 24,719 | 2,646,552 | SH | DFND | 3 | 0 | 0 | 0 | |
| Pharmacyclics, Inc. | COM | 716933106 | 67,333 | 636,542 | SH | DFND | 2 | 0 | 0 | 0 | |
| Regeneron Pharmaceuticals, Inc. | COM | 75886F107 | 52,846 | 192,000 | SH | DFND | 2 | 0 | 0 | 0 | |
| Synageva BioPharma Corp. | COM | 87159A103 | 55,579 | 858,757 | SH | DFND | 3 | 0 | 0 | 0 | |
| Theravance Inc. | COM | 88338T104 | 31,666 | 888,244 | SH | DFND | 3 | 0 | 0 | 0 | |
| Tesaro, Inc. | COM | 881569107 | 13,309 | 471,282 | SH | DFND | 3 | 0 | 0 | 0 | |
| Vertex Pharmaceuticals Inc. | COM | 92532F100 | 104,350 | 1,404,445 | SH | DFND | 3 | 0 | 0 | 0 | |